Concerns about a vaccine preservative long thought put to rest are roaring back to life as a United Nations program considers a worldwide ban on the additive.
The FDA gave the OK to GlaxoSmithKline's new four-strain seasonal flu vaccine, which the company said will become available for the 2013-2014 flu season.
University of Cape Town's South African Tuberculosis Vaccine Initiative and Stellenbosch's Desmond Tutu TB Centre are recruiting infants to test a new tuberculosis vaccine for newborns of HIV-positive moms, a demographic not served by the current vaccine.
The global pediatric vaccine market will likely hit a value of more than $23 billion by 2015, a market analysis shows. GlaxoSmithKline leads the charge with nearly a quarter of the global market.
The Bill & Melinda Gates Foundation awarded $10 million to Seattle, WA-based IDRI for formulating new and improved vaccine adjuvants, focusing predominantly on tuberculosis.
The GAVI Alliance wants to immunize 30 million girls worldwide with HPV vaccines by 2020.
Startup Nuron Biotech acquired from Pfizer a vaccine to protect against meningitis, sepsis and pneumonia for an undisclosed amount.
GlaxoSmithKline will take advantage of the ubiquitous mobile phone to increase vaccination rates in Africa. The pharma giant is teaming up with British mobile phone group Vodafone to use text messages to alert mothers about the availability of vaccinations and help them to schedule appointments.
Fraunhofer Center for Molecular Biotechnology could receive up to $9.9 million in funding from NIH's National Institute of Allergy and Infectious Diseases to develop the next generation of anthrax vaccines.
An early flu season is under way, the national Centers for Disease Control and Prevention reports, and will likely prove formidable.
After losing more than 1 million service days during the Iraq and Afghanistan wars to severe diarrhea in troops, the Defense Advanced Research Projects Agency wants to combat the problem by making drugs based on nucleic acids such as DNA rather than the weakened or dead proteins typically used in vaccines.
Protein Sciences expands flu vaccine operations to Pfizer site
Protein Sciences will lease two buildings at Pfizer's Pearl River, NY, site to create a production line for its recombinant influenza vaccine Flublok.
North Dakota-based Altravax landed two research grants worth $3.45 million from NIH's National Institute of Allergy and Infectious Diseases for research on HIV-1 vaccines that induce antibody production.
Health Canada gave the nod to Sanofi Pasteur Canada to expand the indication for Menactra to infants 9 months of age.
Two weeks ago, an FDA panel dealt a blow to Dynavax Technologies, raising concerns about the safety of the company's hepatitis B vaccine, Heplisav. Shares dropped and investors tend to turn their backs on a company when stock prices go down. But is the company's future really all that grim?
Pollen husks deliver vaccines to the gut
Pollen grains--the frustrating cause of sneezing, runny noses and itchy eyes in those with hay fever--could prove an effective method for delivering oral vaccines.
A virus found in man's best friend may offer a platform for developing a potent human vaccine.
A Danish-made tuberculosis vaccine sickened more than 100 children in Romania, according to a European Centre for Disease Prevention and Control report.
Selecta inks $900M immunotherapy deal with Sanofi
Selecta Biosciences, a U.S. vaccine company, inked a deal worth as much as $900 million with Sanofi to work on immunotherapies for life-threatening food allergies.